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Although prolonged exposure (PE) has received the most empirical support of any treatment for post-
traumatic stress disorder (PTSD), clinicians are often hesitant to use PE due to beliefs that it is contraindicated
for many patients with PTSD. This is especially true for PTSD patients with comorbid problems. Because
PTSD has high rates of comorbidity, it is important to consider whether PE is indeed contraindicated for
patients with various comorbid problems. Therefore, in this study, we examine the evidence for or against the
use of PE with patients with problems that often co-occur with PTSD, including dissociation, borderline
personality disorder, psychosis, suicidal behavior and non-suicidal self-injury, substance use disorders,
and major depression. It is concluded that PE can be safely and effectively used with patients with these
comorbidities, and is often associated with a decrease in PTSD as well as the comorbid problem. In cases
with severe comorbidity, however, it is recommended to treat PTSD with PE while providing integrated or
concurrent treatment to monitor and address the comorbid problems.
Keywords: PTSD; comorbidity; prolonged exposure; (contra)indications
For the abstract or full text in other languages, please see Supplementary files under Reading Tools
online
Received: 17 May 2012; Revised: 28 June 2012; Accepted: 4 July 2012; Published: 25 July 2012
M
any controlled studies have demonstrated
the efficacy of prolonged exposure (PE; Foa,
Hembree, & Rothbaum, 2007), an exposure-
based form of cognitive behavioral therapy focused on
reducing PTSD and related psychopathology (see for a
meta-analysis Powers, Halpern, Ferenschak, Gillihan, &
Foa, 2010). PE includes components of psychoeducation,
in vivo exposure to feared but safe trauma-related stimuli,
imaginal exposure, and processing of trauma memories.
PE is thought to work through fear extinction mechan-
isms, allowing the patient to emotionally engage and
process the traumatic memories in the absence of
feared outcomes (e.g., Foa et al., 2007). On the basis
of the numerous studies demonstrating its efficacy, PE is
considered a treatment of choice for PTSD (Ballinger
et al., 2004; Nemeroff et al., 2006) and is recommended
world-wide in official PTSD treatment guidelines, e.g.,
International Society for Traumatic Stress Studies (Foa,
Keane, Friedman, & Cohen, 2009); National Institute
for Health and Clinical Excellence Guidelines on PTSD
(NICE, 2005). Indeed, in a report by the Institute of
Medicine (2007), exposure therapy was considered the
only form of PTSD treatment with a sufficient evidence
base. Furthermore, gains made in PE are maintained in
long-term follow-up (510 years post-treatment, Resick,
Williams, Suvak, Monson, & Gradus, 2012). Despite its
efficacy, the dissemination of PE to clinical practice has
been challenging, as is illustrated by the underuse of this
treatment by therapists. In a survey of psychologists in
the USA, only 17% reported using imaginal exposure to
treat PTSD (Becker, Zayfert, & Anderson, 2004). Simi-
larly, a survey of European trauma experts found that
imaginal exposure was the least used treatment for PTSD
(Van Minnen, Hendriks, & Olff, 2010).
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One of the primary reasons that clinicians report for
not using PE techniques is a belief that the treatment is
contraindicated for PTSD patients with various comor-
bid diagnoses and problems. In the study by Becker et al.
(2004), for instance, many clinicians viewed imaginal
exposure as contraindicated for patients with comorbid
suicidality (85%), psychotic disorder (85%), dissociation
(51%), any comorbid diagnosis (37%), or a comorbid
anxiety disorder (32%). One of the main reasons for not
employing PE was fear of exacerbation of symptoms
(both of PTSD symptoms and comorbid symptoms).
Similarly, the study by Van Minnen et al. (2010) found
that clinicians believed PE was less indicated for patients
with depression, especially when they had suffered multi-
ple childhood traumas. In addition, the consensus among
some PTSD experts (Cloitre et al., 2011) is that a treat-
ment approach based primarily on memory processing
(such as PE) is inappropriate for cases of ‘‘complex’’
PTSD (i.e., PTSD with associated features such as dis-
sociative symptoms and dysregulation of affect and
behavior, for definitions see also Sar, 2011). However,
given the fact that PTSD has high rates of comorbidity
(7988.3%; Kessler, Sonnega, Bromet, Hughes, & Nelson,
1995), these perceived contraindications would lead to
the exclusion of the majority of PTSD patients from PE.
The PE manual (Foa et al., 2007) specifies several
clinically determined contraindications for treatment:
imminent threat of suicidal or homicidal behavior, recent
(past 3 months) serious self-injurious behavior, and
current psychosis. Substance abuse and dependence are
not exclusion criteria per se, but it is recommended to
address the substance use disorder simultaneously with
PE. Patients with dissociative disorders are included, as
long as the dissociative symptoms do not outweigh the
PTSD symptoms. With regard to Axis II disorders,
patients are only excluded from PE when the disorder is
severe (e.g., in the case of borderline personality disorder
(BPD) with current, serious self-injurious or destructive
behavior).
Several studies have specifically addressed the ques-
tion of whether comorbidity is a predictor of treatment
outcome in PE (e.g., Feeny, Zoellner, & Foa, 2002;
Speckens, Ehlers, Hackmann, & Clark, 2006; Van
Minnen, Arntz, & Keijsers, 2002). No study found that
comorbidity (including depression, dissociation, per-
sonality disorders, and substance use) predicted worse
treatment outcome. Indeed, very few pretreatment vari-
ables were found to predict the outcome of PE. Therefore,
patients should not be excluded from this highly effective
treatment based on pretreatment characteristics such
as comorbidity. However, some experts argue that these
findings are not representative because patients with
severe comorbidity are often excluded from randomized
controlled trials (RCTs) of PE (e.g., Spinazolla, Blaustein,
& Van der Kolk, 2005).
To encourage the use of PE in clinical practice, it
is important that clinicians are informed about valid
indications and contraindications for PE. To that
end, we review the research that has evaluated whether
comorbid conditions and problems that are highly
prevalent in PTSD patients are indeed contraindications
for PE. These include dissociation, BPD, psychosis,
suicidal and non-suicidal self-injury, substance use dis-
orders, and major depression. We address the possible
theoretical and clinical reasons why each particular
comorbid condition or problem might interfere with PE.
Also, we explore to what extent these comorbidities are
indeed excluded in RCTs concerning PE using the studies
included in the Powers et al.’s (2010) meta-analysis as a
starting point (Table 1). In addition, we review the
predictive value of comorbid problems in relation to PE
treatment outcome. Lastly, we review the available re-
search on PE for these patients, including results from
RCTs as mentioned in the Powers et al.’s (2010) study, as
well as effects derived from open and pilot studies of PE or
modified PE treatment programs, specifically aimed at
treating the above-mentioned comorbid populations.
Dissociation
Many patients with PTSD have at least some symptoms
of dissociation. The DSM-IV describes dissociation as,
‘‘a disruption in the usually integrated functions of con-
sciousness, memory, identity, or perception of the envir-
onment’’ (p. 477). Derealization and depersonalization
are the most common dissociative symptoms among
PTSD patients. A review showed that 30% of war
veterans with PTSD reported elevated levels of derealiza-
tion (Hunter, Sierra, & David, 2004). In addition, several
dissociative symptoms, such as numbing, are among the
diagnostic criteria of PTSD. In light of the Becker et al.’s
(2004) study, in which 51% of clinicians considered any
kind of dissociation a contraindication for PE, it would
mean that many PTSD patients would be excluded. In the
PE manual (Foa et al., 2007), severe dissociation and
dissociative disorders were not considered contraindica-
tions for the use of PE unless the dissociation symptoms
are much more prominent than the PTSD symptoms.
Clinicians argue that they are concerned about exacer-
bations of dissociative symptoms as a result of PE
(particularly recounting distressing trauma memories).
Theoretically, one could argue that dissociation, espe-
cially emotional numbing, may hinder fear activation and
thereby interfere with emotional processing, a necessary
condition for PE to be successful. Although Taylor et al.
(2001) found that numbing was negatively related to
treatment outcome, other studies found no such relation-
ship (Jaycox, Foa, & Morral, 1998; Speckens et al., 2006).
However, most studies did not control for depression, a
condition closely related to numbing (see Feeny, Zoellner,
Fitzgibbons, & Foa, 2000). In addition, dissociation
Agnes van Minnen et al.
2
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805
T
ab
le
1
.
C
o
-m
o
rb
id
it
y
ex
cl
u
si
o
n
cr
it
er
ia
fr
o
m
th
e
st
u
d
ie
s
o
f
P
o
w
er
s
et
a
l.
(2
0
1
0
)
D
is
s
o
c
ia
ti
o
n
O
u
tl
in
e
p
e
rs
o
n
a
lit
y
d
is
o
rd
e
r
P
sy
c
h
o
s
is
S
u
ic
id
a
l
a
n
d
n
o
n
-s
u
ic
id
a
l
s
e
lf
-i
n
ju
ry
S
u
b
s
ta
n
c
e
u
s
e
d
is
o
rd
e
rs
M
a
jo
r
D
e
p
re
s
s
io
n
A
s
u
k
a
i,
S
a
it
o
,
Ts
u
ru
ta
,
K
is
h
im
o
to
,
&
N
is
h
ik
a
w
a
(2
0
1
0
)
S
e
v
e
re
d
is
s
o
c
ia
ti
o
n
N
/A
H
is
to
ry
o
f
p
s
yc
h
o
s
is
S
e
ri
o
u
s
ri
s
k
o
f
s
u
ic
id
a
l
b
e
h
a
v
io
r
C
u
rr
e
n
t
s
u
b
s
ta
n
c
e
d
e
p
e
n
d
e
n
c
e
D
e
p
re
s
s
io
n
fo
r
w
h
ic
h
d
ru
g
tr
e
a
tm
e
n
t
w
a
s
p
ri
o
ri
ti
ze
d
F
o
a
R
o
th
b
a
u
m
,
R
ig
g
s
,
a
n
d
M
u
rd
o
c
k
(1
9
9
1
)
N
/A
N
/A
C
u
rr
e
n
t
o
r
p
re
v
io
u
s
d
ia
g
n
o
s
is
o
f
s
c
h
iz
o
p
h
re
n
ia
,
p
a
ra
n
o
id
d
is
o
rd
e
rs
,
b
ip
o
la
r
d
is
o
rd
e
r,
o
r
d
e
p
re
s
s
io
n
w
it
h
d
e
lu
s
io
n
s
,
h
a
llu
c
in
a
ti
o
n
s
o
r
b
iz
a
rr
e
b
e
h
a
v
io
r
N
/A
C
u
rr
e
n
t
a
lc
o
h
o
l
o
r
d
ru
g
a
b
u
s
e
D
e
p
re
s
s
io
n
s
e
v
e
re
e
n
o
u
g
h
to
re
q
u
ir
e
im
m
e
d
ia
te
p
s
yc
h
ia
tr
ic
tr
e
a
tm
e
n
t
F
o
a
e
t
a
l.
(1
9
9
9
)
N
/A
N
/A
C
u
rr
e
n
t
s
c
h
iz
o
p
h
re
n
ia
,
b
ip
o
la
r
d
is
o
rd
e
r
S
e
ve
re
s
u
ic
id
a
l
id
e
a
ti
o
n
C
u
rr
e
n
t
a
lc
o
h
o
l
o
r
d
ru
g
d
e
p
e
n
d
e
n
c
e
N
/A
F
o
a
e
t
a
l.
(2
0
0
5
)
N
/A
N
/A
C
u
rr
e
n
t
d
ia
g
n
o
s
is
o
f
s
c
h
iz
o
p
h
re
n
ia
o
r
p
s
yc
h
o
ti
c
d
is
o
rd
e
r
U
n
m
e
d
ic
a
te
d
s
y
m
p
to
m
a
ti
c
b
ip
o
la
r
d
is
o
rd
e
r
H
ig
h
ri
s
k
fo
r
s
u
ic
id
a
l
b
e
h
a
v
io
r
(i.
e
.,
w
it
h
in
te
n
t,
p
la
n
o
r
b
o
th
)
R
e
c
e
n
t
h
is
to
ry
o
f
s
e
ri
o
u
s
s
e
lf
-i
n
ju
ri
o
u
s
b
e
h
a
v
io
r
(i.
e
.,
c
u
tt
in
g
)
C
u
rr
e
n
t
s
u
b
s
ta
n
c
e
d
e
p
e
n
d
e
n
c
e
N
/A
G
ilb
o
a
-S
c
h
e
c
h
tm
a
n
e
t
a
l.
(2
0
1
0
)
N
/A
N
/A
C
u
rr
e
n
t
p
s
yc
h
o
ti
c
s
y
m
p
to
m
s
S
u
ic
id
a
l
id
e
a
ti
o
n
p
o
s
in
g
im
m
in
e
n
t
d
a
n
g
e
r
(s
u
ic
id
a
l
th
o
u
g
h
ts
w
e
re
n
o
t
e
x
c
lu
d
e
d
)
C
u
rr
e
n
t
s
u
b
s
ta
n
c
e
d
e
p
e
n
d
e
n
c
e
N
/A
M
a
rk
s
e
t
a
l.
(1
9
9
8
)
N
/A
N
/A
P
a
st
o
r
p
re
s
e
n
t
p
s
y
c
h
o
s
is
S
u
ic
id
a
l
in
te
n
t
U
s
e
o
f
1
0
m
g
/d
a
y
o
f
d
ia
ze
p
a
m
(o
r
e
q
u
iv
a
le
n
t)
,
in
g
e
s
ti
o
n
o
f
3
0
o
r
m
o
re
u
n
it
s
o
f
a
lc
o
h
o
l
p
e
r
w
e
e
k
M
e
la
n
c
h
o
lia
M
c
D
o
n
a
g
h
e
t
a
l.
(2
0
0
5
)
D
is
s
o
c
ia
ti
v
e
id
e
n
ti
ty
d
is
o
rd
e
r
N
/A
C
u
rr
e
n
t
d
ia
g
n
o
s
is
o
f
m
a
n
ia
,
h
y
p
o
m
a
n
ia
,
s
c
h
iz
o
p
h
re
n
ia
,
s
c
h
iz
o
a
ff
e
c
ti
v
e
d
is
o
rd
e
r,
s
c
h
iz
o
p
h
re
n
if
o
rm
d
is
o
rd
e
r,
b
ri
e
f
re
a
c
ti
v
e
p
s
y
c
h
o
s
is
,
p
s
yc
h
o
ti
c
d
is
o
rd
e
r
N
O
S
B
ip
o
la
r
d
is
o
rd
e
r,
d
e
p
re
s
s
io
n
w
it
h
d
e
lu
si
o
n
s
,
h
a
llu
c
in
a
ti
o
n
s
o
r
b
iz
a
rr
e
b
e
h
a
v
io
r
P
re
s
e
n
c
e
o
f
a
c
ti
v
e
s
u
ic
id
a
lit
y
o
r
h
is
to
ry
o
f
tw
o
o
r
m
o
re
s
u
ic
id
e
a
tt
e
m
p
ts
/g
e
s
tu
re
s
in
p
a
s
t
y
e
a
r
C
u
rr
e
n
t
a
lc
o
h
o
l
o
r
d
ru
g
a
b
u
s
e
,
w
it
h
d
ra
w
a
l
fr
o
m
b
e
n
zo
d
ia
ze
p
in
e
s
,
a
lc
o
h
o
l,
h
e
ro
in
o
r
o
th
e
r
o
p
ia
te
s
in
p
a
s
t
3
m
o
n
th
s
D
e
p
re
s
s
io
n
s
e
v
e
re
e
n
o
u
g
h
to
re
q
u
ir
e
a
c
u
te
p
s
yc
h
ia
tr
ic
tr
e
a
tm
e
n
t
Examining potential contraindications for prolonged exposure
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805 3
(page number not for citation purpose)
T
a
b
le
1
(C
o
n
ti
n
u
e
d
)
D
is
s
o
c
ia
ti
o
n
O
u
tl
in
e
p
e
rs
o
n
a
lit
y
d
is
o
rd
e
r
P
sy
c
h
o
s
is
S
u
ic
id
a
l
a
n
d
n
o
n
-s
u
ic
id
a
l
s
e
lf
-i
n
ju
ry
S
u
b
s
ta
n
c
e
u
s
e
d
is
o
rd
e
rs
M
a
jo
r
D
e
p
re
s
s
io
n
N
a
c
a
s
c
h
e
t
a
l.
(2
0
1
1
)
S
e
v
e
re
d
is
s
o
c
ia
ti
v
e
d
is
o
rd
e
r
N
/A
C
u
rr
e
n
t
p
s
yc
h
o
ti
c
s
y
m
p
to
m
s
B
ip
o
la
r
d
is
o
rd
e
r
H
ig
h
ri
s
k
fo
r
s
u
ic
id
a
l
b
e
h
a
v
io
r
(i.
e
.,
w
it
h
in
te
n
t,
p
la
n
o
r
b
o
th
)
C
u
rr
e
n
t
a
c
ti
v
e
s
u
b
s
ta
n
c
e
d
e
p
e
n
d
e
n
c
e
N
/A
P
o
w
e
r
e
t
a
l.
(2
0
0
2
)
N
/A
N
/A
P
a
st
o
r
p
re
s
e
n
t
p
s
y
c
h
o
ti
c
ill
n
e
ss
S
u
ic
id
a
l
id
e
a
ti
o
n
o
r
in
te
n
t
H
is
to
ry
o
f
a
lc
o
h
o
lis
m
o
r
d
ru
g
a
b
u
s
e
in
p
a
s
t
6
m
o
n
th
s
S
e
v
e
re
d
e
p
re
s
s
iv
e
ill
n
e
s
s
R
e
s
ic
k
,
N
is
h
it
h
,
W
e
a
v
e
r,
A
s
ti
n
,
&
F
e
u
e
r
(2
0
0
2
)
N
/A
N
/A
C
u
rr
e
n
t
p
s
yc
h
o
s
is
S
u
ic
id
a
l
in
te
n
t
C
u
rr
e
n
t
p
a
ra
s
u
ic
id
a
l
b
e
h
a
v
io
r
C
u
rr
e
n
t
d
e
p
e
n
d
e
n
c
e
o
n
d
ru
g
s
o
r
a
lc
o
h
o
l.
In
c
a
s
e
o
f
h
is
to
ry
o
f
s
u
b
s
ta
n
c
e
d
e
p
e
n
d
e
n
c
e
:
B
6
m
o
n
th
s
a
b
s
ti
n
e
n
c
e
N
/A
R
o
th
b
a
u
m
e
t
a
l.
(2
0
0
5
)
N
/A
N
/A
H
is
to
ry
o
f
s
c
h
iz
o
p
h
re
n
ia
o
r
o
th
e
r
p
s
yc
h
o
s
e
s
C
u
rr
e
n
t
s
u
ic
id
a
l
ri
s
k
P
ra
c
ti
c
e
d
s
e
lf
-m
u
ti
la
ti
o
n
C
u
rr
e
n
t
a
lc
o
h
o
l
o
r
d
ru
g
d
e
p
e
n
d
e
n
c
e
,
c
o
c
a
in
e
u
s
e
in
p
a
s
t
6
0
d
a
y
s
N
/A
S
c
h
n
u
rr
e
t
a
l.
(2
0
0
7
)
N
/A
N
/A
C
u
rr
e
n
t
p
s
yc
h
o
ti
c
s
y
m
p
to
m
s
M
a
n
ia
o
r
b
ip
o
la
r
d
is
o
rd
e
r
P
ro
m
in
e
n
t
c
u
rr
e
n
t
s
u
ic
id
a
l
id
e
a
ti
o
n
S
e
lf
-m
u
ti
la
ti
o
n
in
th
e
p
a
s
t
6
m
o
n
th
s
S
u
b
st
a
n
c
e
d
e
p
e
n
d
e
n
c
e
n
o
t
in
re
m
is
s
io
n
fo
r
a
t
le
a
s
t
3
m
o
n
th
s
N
/A
Ta
y
lo
r
e
t
a
l.
(2
0
0
3
)
N
/A
N
/A
C
u
rr
e
n
t
p
s
yc
h
o
ti
c
d
is
o
rd
e
r
N
/A
N
/A
N
/A
Agnes van Minnen et al.
4
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805
is often addressed as a single, general construct, but is in
fact a highly complicated construct, including a variety of
symptoms (Bryant, 2007).
To address these issues, Hagenaars, Van Minnen, and
Hoogduin (2010) studied the effect of dissociation on PE
treatment outcome in 71 PTSD patients, discriminating
among several dissociative phenomena and controlling
for depression. Emotional numbing, depersonalization,
and a general tendency to dissociate did not predict worse
treatment outcome, nor treatment dropout, even in
patients with high levels of these symptoms. On the
contrary, patients with higher levels of dissociation
(specifically numbing) had better outcome compared
with patients with lower levels of numbing. Importantly,
dissociation did not impede fear activation during
exposure to the trauma memories. In this study, the
presence of dissociative disorders was not assessed, but
patients with clinical levels of dissociative symptoms were
included and, when separately analyzed, the results were
not altered. These findings are in line with the recent
findings that adding exposure (in this study writing
accounts, not PE) to cognitive therapy was indicated
for patients with higher levels of dissociation (Resick
Suvak, Johnides, Mitchell, & Iverson, 2012). Of interest,
in the majority of the studies (10/13) included in the
Powers et al.’s (2010) meta-analysis, dissociative symp-
toms or dissociative disorders were not an exclusion
criterion, implying that results found in RCTs may apply
to PTSD patients with (severe) dissociative symptoms.
Taken together, there is no evidence that dissociative
symptoms are a valid contraindication for use of PE, even
for patients with severe and clinical levels of dissociation.
In fact, dissociation was associated with better emotional
processing and enhanced treatment outcome. It is more
likely that dissociation is a dysfunctional avoidance
strategy (see Briere, Scott, & Weathers, 2005), preventing
patients from fully processing their traumatic memories
and thereby maintaining PTSD symptoms. Accordingly,
patients with (severe) dissociative symptoms should not
be excluded from PE, but rather should be encouraged to
overcome their avoidance behavior, as is done in PE,
so that their fear structure can be fully activated and
emotional processing can take place. Consistent with this
view, several studies have found that the symptoms of
dissociation decrease significantly after PE along with
the PTSD symptoms (Hagenaars et al., 2010; Harned,
Korslund, Foa, & Linehan, 2012; Rothbaum, Astin, &
Marsteller, 2005; Taylor et al., 2003).
Borderline personality disorder
Research has indicated that 24.2% of individuals with
PTSD also have BPD (Pagura et al., 2010), and comorbid
BPD is particularly common among women with PTSD
related to childhood sexual abuse (37%; Heffernan &
Cloitre, 2000). Individuals with BPD are often viewed
as inappropriate for exposure therapy for PTSD, includ-
ing PE. These concerns are based on the belief that
BPD patients are unable to tolerate exposure, particularly
imaginal exposure to traumatic memories, and may even
get worse (e.g., become increasingly suicidal, require
psychiatric hospitalization) during such treatment. Theo-
retically, patients with BPD possess a number of char-
acteristics that may interfere with achieving effective
emotional engagement and fear reduction during PE.
A core feature of BPD is pervasive emotion dysregula-
tion, which includes intense emotional reactivity and
avoidance of emotional experiencing (Linehan, Bohus, &
Lynch, 2007). In addition, patients with BPD often use
a variety of maladaptive emotion regulation strategies
(e.g., intentional self-injury, dissociation, substance use)
that may both interfere with fear activation and cause
safety concerns during PE.
Importantly, none of the PE studies in the Powers
et al.’s (2010) meta-analysis excluded patients with
BPD. However, all of the studies excluded patients with
behaviors that commonly co-occur with severe BPD
(e.g., acute suicidality, serious non-suicidal self-injury,
substance dependence). This is consistent with recom-
mendations in the PE manual (Foa et al., 2007), which
states that patients should not be excluded from PE on
the basis of any Axis II diagnosis, but individuals with
severe degrees of personality disorders may be excluded
for other reasons (e.g., cases of BPD with serious self-
injurious behaviors). When these standard PE exclusion
criteria are used, several studies have shown that patients
with BPD or borderline personality characteristics (BPC)
improve as much as those without BPD/BPC during
standard PE (Clarke, Rizvi, & Resick, 2008; Feeny et al.,
2002). In addition, four studies of modified PE treat-
ments for childhood abuse-related PTSD have reported
including BPD patients in their samples, including an
RCT of a 16-week outpatient treatment involving skills
training followed by modified PE (Cloitre et al., 2010), an
RCT of a 14-week outpatient modified PE treatment
(McDonagh et al., 2005), an open trial of a 3-month
residential Dialectical Behavior Therapy (DBT) and
modified PE program (Bohus, Kruger, Dyer, Priebe, &
Steil, 2011), and case studies of a brief (5-day) intensive
outpatient treatment based on PE (Hendriks, de Kleine,
van Rees, Bult, & van Minnen, 2010). However, only
one of these studies examined the impact of BPD
on treatment outcome, finding that patients with and
without BPD improved comparably (Bohus et al., 2011).
All of these modified PE studies included patients with
recent non-suicidal self-injury, but excluded patients
with recent and/or acute suicidality.
To examine whether these results generalize to even
more severe BPD patients, Harned et al. (2012) con-
ducted an open trial of an integrated DBT and PE
treatment for recently suicidal and/or self-injuring BPD
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women with PTSD (n13). This one-year treatment uses
standard DBT to target intentional self-injury and other
forms of behavioral dyscontrol prior to implementing PE
simultaneously with ongoing DBT. PE was modified by
incorporating DBT skills and strategies (e.g., for mon-
itoring and managing suicide risk) into the standard
PE protocol and was implemented in an average of
13.5 weekly sessions during the year of standard DBT
(for details see Harned, in press). From pre- to post-
treatment, the patients with severe BPD in this study
showed large and significant improvements in PTSD
(d1.4, 70% reliable improvement, 60% remission),
intentional self-injury, and a variety of secondary
trauma-related outcomes (e.g., dissociation, trauma-
related guilt, shame). No patients exhibited reliable
worsening of PTSD or intentional self-injury. In addition,
treatment dropout was low (23%) and occurred only
before the initiation of PE.
Taken together, there is no empirical support for
excluding patients with BPD from PE who meet the
eligibility criteria specified in the PE manual. Indeed,
several studies have shown that patients with mild BPD
are effectively treated with standard PE. In addition,
several studies examining modified PE treatments (deliv-
ered alone or in combination with DBT or DBT skills
training interventions) have shown promising results
among more severe BPD patients who are typi-
cally excluded from PE (e.g., those with recent serious
self-injurious behaviors). Additional research is needed
to further evaluate the efficacy of these modified PE
treatments, to examine the potential impact of BPD on
treatment outcome, and to determine how best to match
these various treatment options to BPD patients with
different levels of disorder.
Psychosis
Many patients with psychotic disorders have been ex-
posed to traumatic events (see Read, Van Os, Morrison,
& Ross, 2005, for a review), and the prevalence of PTSD
in individuals with psychotic disorders is relatively high,
ranging from 12% to 29% (Achim et al., 2011; Buckley,
Miller, Lehrer, & Castle, 2009). Theoretically, active
psychotic symptoms may interfere with the underlying
working mechanism of exposure therapy. It may be more
difficult for these patients to regulate their emotions,
and, in the absence of adequate reality testing, adequate
processing of traumatic memories may be hindered.
In line, most clinicians see psychotic symptoms as a
contraindication for trauma-focused treatments, such as
PE, mainly because they are afraid that this will result in
adverse events, such as exacerbation of psychotic symp-
toms, or an increase in crisis interventions or hospital
admissions (Becker et al., 2004; Read, Hammersley, &
Rudegeair, 2007; Young, Read, Barker-Collo, & Harrison,
2001).
Consistent with the exclusion criteria recommended in
the PE manual (Foa et al., 2007), patients with current
psychotic disorders were excluded from nearly all of
the studies in the Powers et al.’s (2010) meta-analysis.
In addition, five studies excluded patients with past
(non-active) psychotic disorders. Consequently, these
studies do not provide information as to whether PE
can be applied to patients with either past or present
psychotic disorders.
In an open trial, the effects of PE were studied in
patients with a past year history of schizophrenia or
schizoaffective disorder (n20; Frueh et al., 2009).
Treatment consisted of a pre-exposure treatment phase
(14 sessions containing psycho-education, anxiety man-
agement therapy and social skills training) followed by
eight PE sessions. All patients received biweekly usual
care of their case-manager during the trial and, when
indicated, psychopharmacological management of their
psychiatric symptoms. A significant reduction of PTSD
symptoms was noted during and after PE. Nearly all
completers (12 of 13) lost their PTSD diagnosis at
post-treatment, and these effects were maintained at a
3-month follow-up. Importantly, no adverse events were
noted during PE. These results suggest that patients with
psychotic vulnerability can receive PE and benefit from it.
However, seven (35%) of the patients dropped out before
the start of PE, leaving the question open as to whether
this rather long pretreatment phase is necessary. To
address this question, De Bont, Van Minnen, and de
Jongh (2012) applied standard PE to patients with
(present) psychotic disorders (n5) using a randomized
baseline controlled design. In this study, PE included
a maximum of 12 sessions within 12 weeks and was
delivered without modification except for one pretreat-
ment session dedicated to the formulation of a crisis
intervention plan. Patients also continued to receive
concurrent care as usual, including pharmacological
treatment and monitoring and case management, pro-
vided within the same service, but by another care-giver
than the PE therapist. All four completers showed good
treatment results and lost their PTSD diagnosis at the
3-month follow-up. Also no adverse effects (hospital
admissions, suicidal behavior, non-suicidal self-injury,
crisis interventions) were noticed, and active psychotic
symptoms did not increase during treatment. On the
contrary, symptoms of psychotic prone thinking style and
general psychopathology decreased significantly during
treatment.
In sum, there is some evidence that the standard
protocol of PE (even without any modifications) can be
effective and safe for PTSD patients with comorbid
psychosis. However, most studies excluded currently
psychotic patients and the positive data included only a
few patients with only short-term follow-up, thus more
research is needed.
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Suicidal and non-suicidal self-injury
Individuals with PTSD are seven times more likely to
attempt suicide and five times more likely to report
suicidal ideation than those without PTSD (Cougle,
Keough, Riccardi, & Sachs-Ericsson, 2009). Among
suicide ideators, PTSD is the only Axis I disorder that
predicts which individuals will go on to make a suicide
plan and attempt suicide (Nock, Hwang, Sampson, &
Kessler, 2010). Rates of non-suicidal self-injury (i.e.,
intentional self-injury without suicidal intent) are also
high in clinical samples of PTSD patients (5060%;
Cloitre, Koenen, Cohen, & Han, 2002; Dyer et al.,
2009; Zlotnick, Mattia, & Zimmerman, 1999). Expert
consensus and PTSD practice guidelines recommend
excluding individuals with acute suicidality (i.e., suicide
ideation with intent to commit suicide) from PTSD
treatments as clinically appropriate care requires a focus
on reducing the suicide risk before addressing the
PTSD (e.g., Department of Veterans Affairs/Department
of Defense, 2004; Foa et al., 2009; Forbes et al., 2007).
Similarly, the PE manual (Foa et al., 2007) recommends
that individuals at imminent risk of suicide and those
who have attempted suicide or engaged in serious non-
suicidal self-injury in the past 3 months should be
excluded from treatment until these behaviors are suffi-
ciently stabilized. These clinical guidelines have been
adopted in most studies of PE. Of the 13 studies in the
Powers et al.’s (2010) meta-analysis, acutely suicidal
patients were excluded in eleven studies and indirectly
excluded in two studies (e.g., by requiring PTSD to be the
primary or most severe presenting problem). In addition,
four studies excluded individuals with recent non-suicidal
self-injury. Of note, individuals with current suicidal
ideation (without intent to commit suicide) and those
with a history of attempting suicide (prior to the past
3 months) are included in most PE studies; however,
these indices of elevated suicide risk predicted worse
PTSD outcome in patients receiving cognitive therapy
or imaginal exposure (Tarrier, Sommerfield, Pilgrim, &
Faragher, 2000).
Harned et al.’s (2012) open trial is the first to
specifically evaluate PE, in combination with DBT, for
recently and/or imminently suicidal and self-injuring
PTSD patients with BPD. This treatment uses standard
DBT to target suicidal and non-suicidal self-injury and
requires patients to achieve 2 months of abstinence from
these behaviors and to not be at imminent risk of suicide
prior to beginning the PE portion of the treatment (see
BPD section above for a description). Urges to commit
suicide and self-injure are monitored before and after
each exposure task, and DBT is used to address any
increases in urges as well as actual episodes of these
behaviors that may occur. Results of the open trial
indicate that it is safe to use PE within a DBT program
in this high-risk population. Urges to commit suicide and
self-injure rarely increased immediately after completing
an exposure task (B7% of tasks), and the rate of relapse
of these behaviors during PE was low (10%). Similarly,
a study of a residential treatment for childhood sexual
abuse-related PTSD that included actively self-injuring
patients did not find an increase in non-suicidal self-
injury during modified PE that occurred in the context of
a DBT treatment (Bohus et al., 2011).
In sum, there is no empirical evidence to support the
use of PE with patients with a recent (past 2 months)
suicide attempt or patients who are acutely suicidal
(suicidal ideation with intent to commit suicide). Further,
although several PE or modified PE studies have not
reported excluding patients with recent serious non-
suicidal self-injury, only one study has reported results
related to self-injury, making it difficult to determine the
safety or efficacy of PE for actively self-injuring patients.
Thus, there is currently insufficient evidence to support
the use of PE with patients with recent (past 2 months)
serious non-suicidal self-injury. However, research does
support the use of PE after 2 months of abstinence from
suicide attempts and serious non-suicidal self-injury and
once suicide risk is no longer acute. For acutely suicidal
and self-injuring patients, preliminary data suggests that
DBTmay be effective for achieving the stability necessary
to begin PE as well as for concurrently monitoring and
addressing these behaviors during PE; however, rando-
mized controlled studies are needed to reach more firm
conclusions.
Substance use disorders
PTSD and substance use disorders (SUDs; i.e., abuse
or dependence on alcohol or other drugs) frequently
co-occur. Epidemiologic research has demonstrated that
one-third of individuals with PTSD have a comorbid
SUD (Mills, Teesson, Ross, & Peters, 2006). The most
common SUDs among individuals with PTSD are
alcohol, sedative, and cannabis use disorders; however,
PTSD is most strongly associated with sedative, opioid,
and amphetamine use disorders (Cottler, Compton,
Mager, Spitznagel, & Janca, 1992; Mills et al., 2006). It
is important to note that approximately 45% of indivi-
duals with PTSD also smoke tobacco (Lasser et al.,
2000); however, nicotine dependence is not included in
our discussion of SUD here. Caffeine is also not included
in our discussion; however, with the growing use of highly
caffeinated energy drinks (Reissig, Strain, & Griffiths,
2009), it is also important to consider caffeine use among
PTSD patients given its anxiogenic effects.
There is much controversy with regard to the use of PE
in individuals with SUD. Traditionally, PE was consid-
ered inappropriate for use among patients with SUD
(Foa & Rothbaum, 1998), as it was widely believed that
these patients would be unable to cope with the intense
emotions elicited during PE, placing them at increased
Examining potential contraindications for prolonged exposure
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805 7
(page number not for citation purpose)
risk for relapse (Becker et al., 2004; Killeen, Back, &
Brady, 2011). It has also been suggested that substance
use may impair fear activation and processing of new
information, thereby reducing treatment effectiveness,
and that cognitive impairment associated with SUD
may impair patients’ ability to undertake imaginal ex-
posure (Ouimette, Moos, & Brown, 2003). Therefore,
historically it was recommended that PE should only be
employed with SUD patients once a period of abstinence
(typically between 3 to 9 months), or a substantial
reduction in use, had been achieved (Back, 2010; Becker
et al., 2004; Najavits, 2006; Ouimette et al., 2003).
On the basis of these assumptions, patients with
substance dependence have been excluded from most
trials of PE. Seven studies included in the Powers et al.’s
(2010) meta-analysis explicitly excluded current sub-
stance dependence (but not abuse); however, only two
studies provided definitions of what was meant by
‘‘current’’: 3 and 6 months. Conversely, some studies
specified current substance abuse (but not dependence)
as an exclusion criterion. Others included additional
criteria such as not having used any cocaine within 60
days (Rothbaum et al., 2005) and not having experienced
withdrawal in the past 3 months (McDonagh et al.,
2005). The study by Marks, Lovell, Noshirvani, Livanou,
and Thrasher (1998) appears to be the only study to have
included individuals with substance dependence; 16% of
the sample met criteria for alcohol abuse or dependence.
The impact of these disorders on treatment outcome,
however, was not examined. There is, however, some
evidence to suggest that alcohol use during treatment
is associated with drop-out from treatment, and that
benzodiazepine use may also be associated with poorer
treatment outcome (van Minnen et al., 2002).
A number of clinical researchers have begun investi-
gating the efficacy of integrated treatment programs
(i.e., programs that address PTSD and SUD simulta-
neously by the same clinician or service) that incorporate
PE techniques. Typically this involves psycho-education
regarding each disorder and their interrelatedness, coping
skills training, relapse prevention, and trauma-focused
PTSD treatment incorporating imaginal and/or in vivo
exposure (Back, Dansky, Carroll, Foa, & Brady, 2001;
Back et al., 2012; Najavits, Schmitz, Gotthardt, & Weiss,
2005; Triffleman, Carroll, & Kellogg, 1999). This combi-
nation of active PTSD treatment while engaging in
concurrent substance use treatment is also recommended
in the PE manual (Foa et al., 2007). Support for these
programs is growing with an increasing number of studies
providing evidence for their safety and efficacy. Patients
in these studies did not get worse or demonstrate high
rates of relapse; on the contrary, they demonstrated
improvements in relation to both substance use and
PTSD outcomes (Brady, Dansky, Back, Foa, & Carroll,
2001; Mills et al., 2012; Najavits et al., 2005; Triffleman,
2000).
However, the extant research is largely limited to small
pilot studies, with only one large RCT completed to date.
Mills et al. (2012) recently completed an RCT evaluating
the efficacy of an integrated treatment called Concurrent
Treatment of PTSD and Substance Use Disorders Using
Prolonged Exposure (COPE). Compared to treatment as
usual (TAU), individuals who received COPE plus TAU
demonstrated a significantly greater reduction in PTSD
symptom severity over the 9-month follow-up period.
Although the dearth of methodologically sound treat-
ment trials makes it difficult to draw firm conclusions
(van Dam, Vedel, Ehring, & Emmelkamp, 2012), findings
from the aforementioned studies provide support for the
use of integrated treatments that incorporate PE among
individuals with SUD. For PTSD patients with a period
of abstinence (3 or more months) or substance abuse
only, standard PE without additional modifications is
commonly utilized. Although treatment retention for
patients with comorbid SUD is challenging, dropout
rates for PE programs are similar to those observed in
studies of non-trauma focused therapies (Hien et al.,
2009; Najavits, Weiss, Shaw, & Muenz, 1998). Further-
more, as with studies of PE among non-SUD patients,
dropout tends to occur prior to the onset of PE (Brady
et al., 2001; Mills et al., 2012). In sum, while SUD may
complicate PTSD treatment, it should not preclude it.
While research on the use of PE in SUD clients is in its
infancy, a growing number of studies are demonstrating
the safety and efficacy of integrated treatment programs
that utilize PE in this population.
Major depressive disorder
PTSD and major depression commonly co-occur, with
approximately 4050% of those in PE clinical trials
reporting current major depressive disorder (MDD) and
the majority of these patients showing elevated symptoms
of depression severity (e.g., Foa et al., 2005; Resick
et al., 2008; Schnurr et al., 2007). PTSD and MDD are
significantly correlated with one another (.50) at levels
similar to other anxiety disorders (.42.60; Kessler, Chiu,
Demler, & Walters, 2005). Most notably, PTSD with
comorbid MDD is associated with greater disorder
severity (e.g., Kessler et al., 2005), including higher
PTSD, anxiety, and depression and worse functioning
than individuals with either PTSD or MDD alone (see
Post, Zoellner, Youngstrom, & Feeny, 2011). This greater
disorder severity likely underlies clinicians’ concerns
about PTSD patients with co-occurring MDD being
harder to engage in a behavioral treatment, having
more difficulty tolerating exposure, and having more
indelible negative beliefs such as hopelessness, guilt,
low self-efficacy, and rumination. Comorbid depression,
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however, is not an exclusion criterion for PE (Foa
et al., 2007).
PTSD and depression not only share common ob-
servable symptoms (e.g., anhedonia, sleep problems,
irritability, concentration difficulties), but also share
underlying factors such as impaired emotion regulation
and negative affect. Some have argued that the distinction
between chronic PTSD and chronic PTSD with co-
morbid depression may be arbitrary and only reflects
greater disorder severity (e.g., O’Donnell, Creamer, &
Pattison, 2004). Extending this to therapeutic mechan-
isms, the mechanisms underlying fear extinction and
depression-related behaviors show significant genetic,
molecular, and neuroanatomical overlap (e.g., Tronson
et al., 2008). Accordingly, it is not surprising to hypothe-
size that, through fear extinction occurring during in vivo
and imaginal exposure in PE, depression symptoms
would also improve due to a shared common mechanism
for fear and mood regulation.
Indeed, this is the case. All of the PE trials in the Powers
et al.’s (2010) meta-analysis included comorbid MDD,
as long as PTSD was considered the primary diagnosis.
Thus, patients with depression that was much more
severe than their PTSD were routinely excluded from
these trials. All but one large-scale clinical trial on PE
measured depression as a secondary outcome, and, of
these studies, all show clinically significant improvements
in depression. In this meta-analysis, medium size effects
for PE were found across all secondary outcome measures
(post-treatment: Hedges’ g0.77; follow-up: Hedges’ g
0.41). When depression is specifically examined, indivi-
dual studies show consistent moderate-to-large PE effects
(e.g., Cohen’s d0.96; Foa et al., 2005), though smaller
than for PTSD (e.g., Cohen’s d1.37; Foa et al., 2005).
This can easily be explained in that PTSD trials include
individuals who are not depressed, resulting in attenuated
effect sizes for depression. Individuals with more severe
depression also show comparable reductions in PTSD
severity with PE (Feeny, Zoellner, Mavissakalian, &
Roy-Byrne, 2009; Hagenaars et al., 2010). In some studies
with PE, elevated pre-treatment depression severity was
associated with reduced post-treatment PTSD severity
(Feeny et al., 2009; Rizvi, Vogt, & Resick, 2009). Negative
beliefs about oneself, the world, and self-blame also
show improvement with PE, corresponding strongly
with changes in PTSD (Foa & Rauch, 2004; Hagenaars,
van Minnen, & de Rooij, 2011), and, in one study, higher
pre-treatment guilt predicted better treatment outcome
(Rizvi et al., 2009). Finally, there may be a reciprocal
relationship between changes in PTSD and depression in
PE. Post-traumatic symptoms account for more variance
of the change in depression than vice versa, suggesting
that PE may work primarily by reducing posttrau-
matic stress, which in turn reduces depression (Aderka,
Foa, Applebaum, Shafran, & Gilboa-Schechtman, 2011).
Taken together, evidence across randomized trials of PE
consistently shows improvement in depression, and clin-
ical improvement in PTSD occurs even for those who have
higher pre-treatment depression severity. That said, pa-
tients with depression much more severe than their PTSD
or patients with current suicidal intent and behavior, as
discussed above, are routinely excluded from PTSD trials,
as clinically appropriate care would require stabilizing
these issues prior to addressing their PTSD.
Discussion
Given the high rate of comorbid disorders and problems
among PTSD patients, it seems important to examine
whether trauma-focused treatments, such as PE, can
be effectively and safely applied to PTSD patients with
severe comorbidity. Consistent with the inclusion and
exclusion criteria described in the PE manual (Foa et al.,
2007), and supported by RCTs that have utilized these
criteria, PTSD patients with comorbid dissociation,
depression, substance abuse, and/or mild BPD can be
successfully and safely treated with standard PE and the
outcome is comparable to that found in patients without
these comorbidities. In addition, several recent studies
have begun to evaluate the effects of PE in patient
samples with severe comorbidity that have previously
been excluded from RCTs and for whom cautiousness
was recommended in the PE manual: patients with
comorbid serious self-injurious behavior, acute suicidal-
ity, recent suicide attempt, current psychosis and sub-
stance dependence disorders. Although more and larger
controlled trials are needed to draw firm conclusions,
studies have found that PE can be effective and safe for
these patients. These newer treatment programs have
all included methods to simultaneously address PTSD
(via PE or modified PE) and the comorbidity (via other
treatments or strategies specific to those problems). These
integrated or concurrent treatments may be the optimal
approach when using PE with patients with these severe
comorbidities. Of note, in each of these studies, trauma-
focused treatment programs were dosed in the standard
way despite the comorbidity; that is, PE sessions were
scheduled once or twice weekly. In contrast, due to fear of
adverse events, clinicians in routine practice may either
postpone the trauma-focused treatment until the comor-
bid condition is less prominent (which may never occur)
or start the trauma-focused treatment at a low frequency,
alternating trauma-focused treatment sessions with treat-
ment sessions aimed at addressing the comorbid condi-
tions. There is no evidence for or against these as effective
management strategies. However, the latter approach
can be problematic as it may actually impair symptom
improvement given that extinction mechanisms used in
exposure therapy require repeated and prolonged expo-
sure to the feared situations and the trauma-related
memories.
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Importantly, clinicians’ concern that patients with
severe comorbidities will show an exacerbation of symp-
toms after starting PE was not confirmed. On the
contrary, across studies it was consistently found that
patients showed a decrease of comorbid symptoms along
with a decrease in PTSD symptoms. Also, patients with
severe comorbidity did not show an elevated rate of
dropout from PE, and, if dropout occurred, it most often
happened before the implementation of PE. Moreover, no
studies reported reliable worsening of PTSD or comorbid
problems. These findings indicate that PE is not only
effective in reducing PTSD for patients with severe
comorbidity, but is also a tolerable and safe treatment
that is likely to have positive effects on the comorbid
conditions as well. That said, clinically, these comorbid-
ities should not be ignored during PE, but rather carefully
monitored and addressed as needed.
In line with the research findings, a meta-analysis of
the effects of comorbidity on treatment (in most cases
cognitive behavioral treatment) outcome for anxiety
disorders found that comorbidity had a positive influence
on PTSD treatment outcome (Olatunji, Cisler, & Tolin,
2010). A possible explanation could be that PTSD often
precedes or maintains the comorbid conditions and
can therefore in most cases be considered the primary
condition. Further, patients with comorbidities are often
more severe; thus, when they make comparable gains to
those without the comorbidities, treatment effects are
larger.
Despite the fact that standard and modified PE was
found to be effective and safe in patients with severe
comorbidities, treating these patients in clinical practice
may be challenging, especially when a patient has more
than one comorbid condition (which is actually more
common than uncommon). In such cases, clinicians may
make adjustments to tailor PE to the specific needs and
complexities of the patient. For example, when working
with depressed patients, clinicians may have to work
harder to engage the patients with the treatment, as they
may lack interest in psychotherapy (Feeny et al., 2009).
Also, as recommended in the PE manual (2007), clin-
icians may add in vivo exposure tasks to address specific
comorbid symptoms, such as anhedonia and avoidance
by increasing activity levels and targeting areas of
previous enjoyment (e.g., Echiverri, Jaeger, Chen, Moore,
& Zoellner, 2011; Foa, Huppert, & Cahill, 2006). Some
patients with limited emotion regulation skills may need
more help from the clinician to carefully modulate
emotional engagement with the trauma memory (e.g.,
Jaycox, Zoellner, & Foa, 2002), and strategies for helping
patients achieve optimal emotional engagement are
suggested in the PE manual (Foa et al., 2007). Lastly,
clinicians may need to increase patients’ adherence with
homework assignments through between-session phone
contact and incorporation of others in the in vivo
homework assignments. Moreover, these multi-morbid
patients often have severe psychosocial stressors, making
it more difficult for patients to plan and attend treatment
sessions and complete homework assignments. For these
patients, it may be helpful to enhance the treatment
process by, for instance, providing PE in an intensive and
brief format instead of traditional weekly sessions. In a
pilot study (Hendriks et al., 2010), patients with PTSD
with multiple comorbid disorders (n4) received 15
sessions of modified PE within one week. This intensive
treatment was effective in decreasing PTSD symptoms,
was tolerable for patients, had no serious adverse effects,
and none of the patients dropped out. Another way
to enhance PE is to use D-cycloserine, a cognitive en-
hancer of extinction learning, in combination with PE.
In a randomized placebo-controlled trial (de Kleine,
Hendriks, Kusters, Broekman, & van Minnen 2012), it
was found that, in a subgroup of patients with more
severe PTSD, 50-mg D-cycloserine significantly enhanced
the exposure effects. Because patients with comorbidities
may have more severe PTSD symptoms, this enhancing
effect could be especially of clinical relevance for them.
This extinction enhancement approach has been shown
to accelerate gains and produce generally comparable
outcome in other anxiety disorders (Norberg, Krystal, &
Tolin, 2008). Also, other biological treatment approaches
show promise in combination with PE, including parox-
etine (Schneier et al., 2012) and cortisol (Yehuda, Bierer,
Pratchett, & Malowney, 2010). Possibly, these combina-
tion therapies could especially be effective for co-morbid
patients, because of their assumed complimentary mecha-
nisms of action.
In conclusion, the existing research on PE for PTSD
patients with severe comorbidity is encouraging. It seems
that even severely comorbid PTSD patients can profit
from PE in a tolerable and safe way. Typically, in indi-
viduals with dissociation, moderate-to-severe depression,
mild BPD, and substance abuse, standard PE can be
applied. In the case of comorbid substance dependence,
psychosis, severe BPD, acute suicidality, and recent
suicidal or serious non-suicidal self-injury, PE can also
be effectively and safely applied within a treatment pro-
gram monitoring and addressing the comorbidity.
Conflict of interest and funding
There is no conflict of interest in the present study for any
of the authors.
References
Achim, A. M., Maziade, M., Raymond, E., Olivier, D., Me´rette, C.,
& Roy, M. A. (2011). How prevalent are anxiety disorders
in schizophrenia? A meta-analysis and critical review on a
significant association. Schizophrenia Bulletin, 37(4), 811821.
Aderka, I. A., Foa, E. B., Applebaum, E., Shafran, N., & Gilboa-
Schechtman, E. (2011). Direction of influence between
Agnes van Minnen et al.
10
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805
posttraumatic and depressive symptoms during prolonged
exposure therapy among children and adolescents. Journal of
Consulting and Clinical Psychology, 79, 421425.
Asukai, N., Saito, A., Tsuruta, N., Kishimoto, J., & Nishikawa, T.
(2010). Efficacy of exposure therapy for Japanese patients with
posttraumatic stress disorder due to mixed traumatic events:
A randomized controlled study. Journal of Traumatic Stress,
23, 744750.
Back, S. E. (2010). Toward an improved model of treating co-
occurring PTSD and substance use disorders. The American
Journal of Psychiatry, 167(1), 1113.
Back, S. E., Dansky, B. S., Carroll, K. M., Foa, E. B., & Brady, K. T.
(2001). Exposure therapy in the treatment of PTSD among
cocaine-dependent individuals: Description of procedures.
Journal of Substance Abuse Treatment, 21(1), 3545.
Back, S. E., Killeen, T., Foa, E. B., Santa Ana, E. J., Gros, D. F., &
Brady, K. T. (2012). Use of an integrated therapy with
prolonged exposure to treat PTSD and comorbid alcohol
dependence in an Iraq veteran. The American Journal of
Psychiatry, 169, 688691.
Ballinger, J. C., Davidson, J. R. T., Lecrubier, Y., Nutt, D. J.,
Marshall, R. D., Nemeroff, C. B., et al. (2004). Consensus
statement update on posttraumatic stress disorder from the
international consensus group on depression and anxiety.
Journal of Clinical Psychiatry, 65, 5562.
Becker, C., Zayfert, C., & Anderson, E. (2004). A survey of
psychologists’ attitudes towards and utilization of exposure
therapy for PTSD. Behaviour Research and Therapy, 42(3),
277292.
Bohus, M., Kruger, A., Dyer, A., Priebe, K., & Steil, R. (2011).
Residential DBT program for patients with borderline person-
ality disorder and PTSD after childhood sexual abuse: A
controlled randomized trial. Presented at the 8th Annual
NIMH conference of the National Education Alliance for
Borderline Personality Disorder, Seattle, WA.
Brady, K. T., Dansky, B. S., Back, S. E., Foa, E. B., & Carroll, K. M.
(2001). Exposure therapy in the treatment of PTSD among
cocaine-dependent individuals: Preliminary findings. Journal of
Substance Abuse Treatment, 21(1), 4754.
Briere, J., Scott, C., & Weathers, F. (2005). Peritraumatic and
persistent dissociation in the presumed etiology of PTSD.
The American Journal of Psychiatry, 162(12), 22952301.
Bryant, R. A. (2007). Does dissociation further our understanding
of PTSD? Journal of Anxiety Disorders, 21(2), 183191.
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009).
Psychiatric comorbidities and schizophrenia. Schizophrenia
Bulletin, 35(2), 383402.
Clarke, S. B., Rizvi, S. L., & Resick, P. A. (2008). Borderline
personality characteristics and treatment outcome in cognitive-
behavioral treatments for PTSD in female rape victims.
Behavior Therapy, 39, 7278.
Cloitre, M., Courtois, C. A., Charuvastra, A., Carapezza, R.,
Stolbach, B. C., & Green, B. L. (2011). Treatment of complex
PTSD: Results of the ISTSS expert clinician survey on best
practices. Journal of Traumatic Stress, 24, 615627.
Cloitre, M., Koenen, K. C., Cohen, L. R., & Han, H. (2002). Skills
training in affective and interpersonal regulation followed
by exposure: A phase-based treatment for PTSD related to
childhood abuse. Journal of Consulting and Clinical Psychology,
70, 10671074.
Cloitre, M., Stovall-McClough, K. C., Nooner, K., Zorbas, P.,
Cherry, S., Jackson, C. L., et al. (2010). Treatment for PTSD
related to childhood abuse: A randomized controlled trial.
American Journal of Psychiatry, 167, 915924.
Cottler, L. B., Compton, W. M., Mager, D., Spitznagel, E. L., &
Janca, A. (1992). Post-traumatic stress disorder among
substance abusers from the general population. American
Journal of Psychiatry, 149, 664670.
Cougle, J. R., Keough, M. E., Riccardi, C. J., & Sachs-Ericsson, N.
(2009). Anxiety disorders and suicidality in the National
Comorbidity Survey-Replication. Journal of Psychiatric
Research, 43, 825829.
De Bont, P. A. J. M., Van Minnen, A., & de Jongh, A. (submitted).
Prolonged Exposure and EMDR Treatment for PTSD in
patients with psychotic disorders; a randomized multiple
baseline design (N10).
De Kleine, R. A., Hendriks, G. J., Kusters, W. J. C., Broekman,
T. G., & van Minnen, A. (2012). A randomized placebo-
controlled trial of D-Cycloserine to enhance exposure therapy
or posttraumatic stress disorder. Biological Psychiatry, 71, 932
934. doi:10.1016/j.biopsych.2012.02.033.
Department of Veterans Affairs/Department of Defense. (2004). VA/
DoD clinical practice guideline for the management of post-
traumatic stress, version 1.0. Washington, DC: Veterans Health
Administration, Department of Defense.
Dyer, K. F. W., Dorahy, M. J., Hamilton, G., Corry, M., Shannon,
M., MacSherry, A., et al. (2009). Anger, aggression, and self-
harm in PTSD and complex PTSD. Journal of Clinical
Psychology, 65, 10991114.
Echiverri, A., Jaeger, J., Chen, J., Moore, S., & Zoellner, L. A.
(2011). Dwelling in the past: The role of rumination in
the treatment of posttraumatic stress disorder. Cognitive and
Behavioral Practice, 18, 338349.
Feeny, N. C., Zoellner, L. A., & Foa, E. B. (2002). Treatment
outcome for chronic PTSD among female assault victims with
borderline personality characteristics: A preliminary examina-
tion. Journal of Personality Disorders, 16, 3040.
Feeny, N. C., Zoellner, L. A., Mavissakalian, M. R., & Roy-Byrne,
P. P. (2009). What would you choose? Sertraline or prolonged
exposure in community and PTSD treatment seeking women.
Depression and Anxiety, 28, 724731.
Foa, E. B., & Rothbaum, B. O. (1998). Treating the trauma of rape:
Cognitive-behavioral therapy for PTSD. New York: Guilford
Press.
Foa, E. B., Dancu, C. V., Hembree, E. A., Jaycox, L. H., Meadows,
E. A., & Street, G. P. (1999). A comparison of exposure
therapy, stress inoculation training, and their combination
for reducing posttraumatic stress disorder in female assault
victims. Journal of Consulting and Clinical Psychology, 67,
194200.
Foa, E. B., Hembree, E. A., Cahill, S. P., Rauch, S. A. M., Riggs,
D. S., Feeny, N. C., et al. (2005). Randomized trial of
prolonged exposure for posttraumatic stress disorder with
and without cognitive restructuring: Outcome at academic
and community clinics. Journal of Consulting and Clinical
Psychology, 73, 953964.
Foa, E. B., Hembree, E. A., & Rothbaum, B. O. (2007). Prolonged
exposure therapy for PTSD: Emotional processing of traumatic
experiences therapist guide. New York, NY: Oxford University
Press.
Foa, E. B., Huppert, J. D., & Cahill, S. P. (2006). Emotional
processing theory: An update. In B. O. Rothbaum (Ed.),
Pathological anxiety: Emotional processing in etiology and
treatment (pp. 324). New York: Guilford Press.
Foa, E. B., Keane, T. M., Friedman, M. J., & Cohen, J. A. (2009).
Effective treatments for PTSD: Practice guidelines from the
International Society for Traumatic Stress Studies (2nd ed.).
New York: Guilford Press.
Foa, E. B., & Rauch, S. A. M. (2004). Cognitive changes during
prolonged exposure versus prolonged exposure plus cognitive
restructuring in female assault survivors with posttraumatic
Examining potential contraindications for prolonged exposure
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805 11
(page number not for citation purpose)
stress disorder. Journal of Consulting and Clinical Psychology,
72, 879884.
Foa, E. B., Rothbaum, B. O., Riggs, D. S., & Murdock, T. B.
(1991). Treatment of post-traumatic stress disorder in rape
victims: A comparison between cognitivebehavioral proce-
dures and counseling. Journal of Consulting and Clinical
Psychology, 59, 715723.
Forbes, D., Creamer, M., Phelps, A., Bryant, R., McFarlane, A.,
Devilly, G. J., et al. (2007). Australian guidelines for the
treatment of adults with acute stress disorder and post-
traumatic stress disorder. Australian and New Zealand Journal
of Psychiatry, 41, 637648.
Frueh, B. C., Grubaugh, A. L., Cusack, K. J., Kimble, M. O., Elhai,
J. D., & Knapp, R. G. (2009). Exposure-based cognitive-
behavioral treatment of PTSD in adults with schizophrenia
or schizoaffective disorder: A pilot study. Journal of Anxiety
Disorders, 23, 665675.
Gilboa-Schechtman, E., Foa, E. B., Shafran, N., Aderka, I. M.,
Poerwers, M. B., Rachamim, L., et al. (2010). Prolonged
exposure versus dynamic therapy for adolescent PTSD: A pilot
randomized controlled trial. Journal of the American Academy
of Child and Adolescent Psychiatry, 49, 10341042.
Hagenaars, M. A., van Minnen, A., & de Rooij, M. (2011).
Cognitions in prolonged exposure therapy for posttraumatic
stress disorder. International Journal of Clinical and Health
Psychology, 10, 421434.
Hagenaars, M. A., van Minnen, A., & Hoogduin, K. A. L. (2010).
The impact of dissociation and depression on the efficacy of
prolonged exposure treatment for PTSD. Behaviour Research
and Therapy, 48(1), 1927.
Harned, M. S. (in press). Treatment of posttraumatic stress disorder
with comorbid borderline personality disorder: Integrating
dialectical behavior therapy and prolonged exposure. In D.
McKay, & E. Storch (Eds.), Handbook of treating variants and
complications in anxiety disorders. New York: Springer Press.
Harned, M. S., Korslund, K. E., Foa, E. B., & Linehan, M. M.
(2012). Treating PTSD in suicidal and self-injuring women with
borderline personality disorder: Development and preliminary
evaluation of a dialectical behavior therapy prolonged expo-
sure protocol. Behaviour Research and Therapy, 50, 381386.
Heffernan, K., & Cloitre, M. (2000). A comparison of posttraumatic
stress disorder with and without borderline personality dis-
order amone women with a history of childhood sexual abuse:
Etiological and clinical characteristics. Journal of Nervous and
Mental Disease, 188, 589595.
Hendriks, L., de Kleine, R., van Rees, M., Bult, C., & van Minnen,
A. (2010). Feasibility of brief intensive exposure therapy for
PTSD patients with childhood sexual abuse: A brief clinical
report. European Journal of Psychotraumatology, 1, 5626,
doi: http://dx.doi.org/10.3402/ejpt.v1i0.5626
Hien, D. A., Jiang, H., Campbell, A. N. C., Hu, M-C., Miele, G. M.,
Cohen, L. R., et al. (2009). Do treatment improvements in
PTSD severity affect substance use outcomes? A secondary
analysis from a randomized clinical trial in NIDA’s Clinical
Trials Network. The American Journal of Psychiatry, 167(1),
95101.
Hunter, E. C. M., Sierra, M., & David, A. S. (2004). The
epidemiology of depersonalisation and derealisation. A sys-
tematic review. Social Psychiatry and Psychiatric Epidemiology,
39, 918.
Institute of Medicine. (2007). Treatment of PTSD: An assessment of
the evidence. Washington, DC: National Academy of Sciences.
Jaycox, L. H., Foa, E. B., & Morral, A. R. (1998). Influence of
emotional engagement and habituation on exposure therapy
for PTSD. Journal of Consulting and Clinical Psychology, 66,
185192.
Jaycox, L. H., Zoellner, L. A., & Foa, E. B. (2002). Current
perspectives: Cognitive behavior therapy for PTSD in rape
survivors. Journal of Clinical Psychology, 58(8), 891906.
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005).
Prevalence, severity, and comorbidity of 12-month DSM-IV
disorders in the National Comorbidity Survey Replication.
Archives of General Psychiatry, 62, 617627.
Kessler, R. C., Sonnega, A., Bromet, E., Hughes, M., & Nelson,
C. B. (1995). Posttraumatic stress disorder in the National
Comorbidity Survey. Archives of General Psychiatry, 52,
10481060.
Killeen, T. K., Back, S. E., & Brady, K. T. (2011). The use of
exposure-based treatment among individuals with PTSD and
co-occurring substance use disorders: Clinical considerations.
Journal of Dual Diagnosis, 7(4), 194206.
Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U.,
McCormick, D., & Bor, D. H. (2000). Smoking and mental
illness. JAMA: The Journal of the American Medical Associa-
tion, 284(20), 26062610. doi:10.1001/jama.284.20.2606.
Linehan, M. M., Bohus, M., & Lynch, T. R. (2007). Dialectical
behavior therapy for pervasive emotion dysregulation: Theore-
tical and practical underpinnings. In J. Gross (Ed.), Handbook
of emotion regulation (pp. 581605). New York: Guilford Press.
Marks, I., Lovell, K., Noshirvani, H., Livanou, M., & Thrasher, S.
(1998). Treatment of posttraumatic stress disorder by exposure
and/or cognitive restructuring. A controlled study. Archives of
General Psychiatry, 55, 317325.
McDonagh, A., Friedman, M., McHugo, G., Ford, J., Sengupta, A.,
Mueser, K., et al. (2005). Randomized trial of cognitive-
behavioral therapy for chronic posttraumatic stress disorder
in adult female survivors of childhood sexual abuse. Journal of
Consulting and Clinical Psychology, 73, 515524.
Mills, K. L., Teesson, M., Back, S. E., Brady, K. T., Baker, A.,
Hopwood, S., et al. (in press). Integrated exposure based therapy
for co-occurring posttraumatic stress disorder and substance
dependence: A randomized controlled trial. Under review
Mills, K. L., Teesson, M., Ross, J., & Peters, L. (2006). Trauma,
PTSD, and substance use disorders: Findings from the
Australian National Survey of Mental Health and Well-Being.
The American Journal of Psychiatry, 163(4), 652658.
Nacasch, N., Foa, E. B., Huppert, J. D., Tzur, D., Fostick, L.,
Dinstein, Y., et al. (2011). Prolonged exposure therapy
for combat- and terror-related posttraumatic stress disorder:
A randomized control comparison with treatment as usal.
Journal of Clinical Psychiatry, 72, 11741180.
Najavits, L. M. (2006). Present- versus past-focused therapy for
posttraumatic stress disorder/substance abuse: A study of
clinician preferences. Brief Treatment and Crisis Intervention,
6(3), 248254.
Najavits, L. M., Schmitz, M., Gotthardt, S., & Weiss, R. D. (2005).
Seeking safety plus exposure therapy: An outcome study
on dual diagnosis men. Journal of Psychoactive Drugs, 37(4),
425435.
Najavits, L. M., Weiss, R. D., Shaw, S. R., & Muenz, L. R. (1998).
‘‘Seeking safety’’: Outcome of a new cognitive-behavioral
psychotherapy for women with posttraumatic stress disorder
and substance dependence. Journal of Traumatic Stress, 11(3),
437456.
Nemeroff, C. B., Bremner, J. D., Foa, E. B., Mayberg, H. S., North,
C. S., & Stein, M. B. (2006). Posttraumatic stress disorder:
A state-of-the-science review. Journal of Psychiatric Research,
40, 121.
NICE. (2005). Post-traumatic stress disorder (PTSD): The manage-
ment of PTSD in adults and children in primary and secondary
care. London: National Institute for Clinical Excellence.
Agnes van Minnen et al.
12
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805
Nock, M. K., Hwang, I., Sampson, N. A., & Kessler, R. C. (2010).
Mental disorders, comorbidity and suicidal behavior: Results
from the National Comorbidity Survey Replication. Molecular
Psychiatry, 15, 868876.
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A meta-
analysis of d-cycloserine and the facilitation of fear extinction
and exposure therapy. Biological Psychiatry, 63, 11181126.
O’Donnell, M. L., Creamer, M., & Pattison, P. (2004). Posttraumatic
stress disorder and depression following trauma: Understand-
ing comorbidity. The American Journal of Psychiatry, 161,
13901396.
Olatunji, B. O., Cisler, T. M., & Tolin, D. M. (2010). A meta-analysis
of the influence of comorbidity on treatment outcome in the
anxiety disorders. Clinical Psychology Review, 30, 642654.
Ouimette, P., Moos, R. H., & Brown, P. J. (2003). Substance use
disorder-posttraumatic stress disorder comorbidity: A survey
of treatments and proposed practice guidelines. In P. Ouimette,
& P. J. Brown (Eds.), Trauma and substance abuse: Causes,
consequences, and treatment of comorbid disorders (pp. 91110).
Washington, DC: American Psychological Association.
Pagura, J., Stein, M. B., Bolton, J. M., Cox, B. J., Grant, B., &
Sareen, J. (2010). Comorbidity of borderline personality
disorder and posttraumatic stress disorder in the U.S. popula-
tion. Journal of Psychiatric Research, 44, 11901198.
Post, L. M., Zoellner, L. A., Youngstrom, E., & Feeny, N. C. (2011).
Understanding the relationship between co-occurring PTSD
and MDD: Symptom severity and affect. Journal of Anxiety
Disorders, 25, 11231130.
Power, K., McGoldrick, T., Brown, K., Buchanan, R., Sharp, D.,
Swanson, V., et al. (2002). A controlled comparison of eye
movement desensitization and reprocessing versus exposure
plus cognitive restructuring versus waiting list in the treatment
of post-traumatic stress disorder. Clinical Psychology and
Psychotherapy, 9, 299318.
Powers, M. B., Halpern, J. M., Ferenschak, M. P., Gillihan, S. J., &
Foa, E. B. (2010). A meta-analytic review of prolonged
exposure for posttraumatic stress disorder. Clinical Psychology
Review, 30(6), 635641.
Read, J., Hammersley, P., & Rudegeair, T. (2007). Why, when and
how to ask about childhood abuse. Advances in Psychiatric
Treatment, 13(2), 101110.
Read, J., Van Os, J., Morrison, A., & Ross, C. (2005). Childhood
trauma, psychosis and schizophrenia: A literature review with
theoretical and clinical implications. Acta Psychiatrica Scandi-
navica, 112(5), 330350.
Reissig, C. J., Strain, E. C., & Griffiths, R. R. (2009). Caffeinated
energy drinks*A growing problem. Drug and Alcohol Depen-
dence, 99, 110.
Resick, P. A., Galovski, T. E., Uhlmansiek, M. O., Scher, C. D.,
Clum, G. A., & Young-Xu, Y. (2008). A randomized clinical
trial to dismantle components of cognitive processing therapy
for posttraumatic stress disorder in female victims of inter-
personal violence. Journal of Consulting and Clinical Psychol-
ogy, 76, 243258.
Resick, P. A., Nishith, P., Weaver, T. L., Astin, M. C., & Feuer, C. A.
(2002). A comparison of cognitive-processing therapy with
prolonged exposure and a waiting condition for the treatment
of chronic posttraumatic stress disorder in female rape victims.
Journal of Consulting and Clinical Psychology, 70, 867879.
Resick, P. A., Suvak, M. K., Johnides, B. D., Mitchell, K. S., &
Iverson, K. M. (2012). The impact of dissociation on PTSD
treatment with cognitive processing therapy. Depression and
Anxiety, doi:10.1002/da.21938.
Resick, P. A., Williams, L. F., Suvak, M. K., Monson, C. M., &
Gradus, J. L. (2012). Long-term outcomes of cognitive
behavioral treatments for posttraumatic stress disorder among
female rape survivors. Journal of Consulting and Clinical
Psychology, 80, 201210.
Rizvi, S. L., Vogt, D. S., & Resick, P. A. (2009). Cognitive and
affective predictors of treatment outcome in cognitive
processing therapy and prolonged exposure for posttraumatic
stress disorder. Behaviour Research and Therapy, 47, 737743.
Rothbaum, B. O., Astin, M. C., & Marsteller, F. (2005). Prolonged
exposure versus eye movement desensitization and reprocessing
(EMDR) for PTSD rape victims. Journal of Traumatic Stress,
18, 607616.
Sar, V. (2011). Developmental trauma, complex PTSD and the
current proposal of DSM-5. European Journal of Psychotrau-
matology, 2, 5622, doi: http://dx.doi.org/10.3402/ejpt.v2i0.5622
Schneier, F. R., Neria, Y., Pavlicova, M., Hembree, E., Suh, E. J.,
Amsel, L., et al. (2012). Combined prolonged exposure therapy
and paroxetine for PTSD related to the world trade center
attack: A randomized controlled trial. American Journal of
Psychiatry, 169, 8088.
Schnurr, P. P., Friedman, M. J., Engel, C. C., Foa, E. B., Shea, M. T.,
Chow, B. K., et al. (2007). Cognitive behavioral therapy for
posttraumatic stress disorder in women: A randomized con-
trolled trial. JAMA: The Journal of the American Medical
Association, 297(8), 820830.
Speckens, A. E. M., Ehlers, A., Hackmann, A., & Clark, D. M.
(2006). Changes in intrusive memories associated with imaginal
reliving in posttraumatic stress disorder. Journal of Anxiety
Disorders, 20, 328341.
Spinazolla, J., Blaustein, M., & Van der Kolk, B. A. (2005).
Posttraumatic stress disorder treatment outcome research:
The study of unrepresentative samples? Journal of Traumatic
Stress, 18(5), 425436.
Tarrier, N., Sommerfield, C., Pilgrim, H., & Faragher, B. (2000).
Factors associated with outcome of cognitive-behavioural
treatment of chronic post-traumatic stress disorder. Behavior
Research and Therapy, 38, 191202.
Taylor, S., Federoff, I. C., Koch, W. J., Thordarson, D. S., Fecteau,
G., & Nicki, R. M. (2001). Posttraumatic stress disorder arising
after road traffic collisions: Patterns of response to cognitive-
behavior therapy. Journal of Consulting and Clinical Psychol-
ogy, 69, 541551.
Taylor, S., Thordarson, D. S., Maxfield, L., Fedoroff, I. C., Lovell,
K., & Ogrodniczuk, J. (2003). Comparative efficacy, speed, and
adverse effects of three PTSD treatments: Exposure therapy,
EMDR, and relaxation training. Journal of Consulting and
Clinical Psychology, 71, 330338.
Triffleman, E. (2000). Gender differences in a controlled pilot study
of psychosocial treatments in substance dependent patients
with post-traumatic stress disorder: Design considerations and
outcomes. Alcohol Treatment Quarterly, 18(3), 113126.
Triffleman, E., Carroll, K., & Kellogg, S. (1999). Substance
dependence posttraumatic stress disorder therapy: An inte-
grated cognitive-behavioral approach. Journal of Substance
Abuse Treatment, 17(12), 314.
Tronson, N. C., Schrick, C., Fischer, A., Sananbenesi, F., Page`s, G.,
Pouysse´gur, J., et al. (2008). Regulatory mechanisms of fear
extinction and depression-like behavior. Neuropsychopharma-
cology, 33, 15701583.
Van Dam, D., Vedel, E., Ehring, T., & Emmelkamp, P. M. G. (2012).
Psychological treatments for concurrent posttraumatic stress
disorder and substance use disorder: A systematic review.
Clinical Psychology Review, 32(3), 202214.
Van Minnen, A., Arntz, A., & Keijsers, G. P. J. (2002). Prolonged
exposure in patients with chronic PTSD: Predictors of treat-
ment outcome and dropout. Behaviour Research and Therapy,
40(4), 439457.
Examining potential contraindications for prolonged exposure
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805 13
(page number not for citation purpose)
Van Minnen, A., Hendriks, L., & Olff, M. (2010). When do trauma
professionals choose exposure therapy for PTSD-patients?
A controlled study about the influence of therapist and patient
factors. Behaviour Research and Therapy, 48, 312320.
Yehuda, R., Bierer, L. M., Pratchett, L., & Malowney, M. (2010).
Glucocorticoid augmentation of prolonged exposure therapy:
Rationale and case report. European Journal of Psychotrauma-
tology, 1, 5643, doi: http://dx.doi.org/10.3402/ejpt.v1i0.5643
Young, M., Read, J., Barker-Collo, S., & Harrison, R. (2001).
Evaluating and overcoming barriers to taking abuse histories.
Professional Psychology: Research and Practice, 32, 407414.
Zlotnick, C., Mattia, J. I., & Zimmerman, M. (1999). Clinical
correlates of self-mutilation in a sample of general psychiatric
patients. Journal of Nervous and Mental Disease, 187, 296301.
*Agnes van Minnen
Behavioural Science Institute
Radboud University Nijmegen
NijCare, the Netherlands
Tel: 31 (24) 82 00 200
Email: a.van.minnen@propersona.nl
Agnes van Minnen et al.
14
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2012, 3: 18805 - http://dx.doi.org/10.3402/ejpt.v3i0.18805
